Optimi Health Corp. (CSE: OPTI / OTCQX: OPTHF / FRA: 8BN) has received a termination notice and demand for payment pursuant to a definitive supply agreement (the “Supply Agreement”) with a private entity focused on developing mushroom-based therapeutics.
For further details of the Supply Agreement, see the Company’s press release dated May 4, 2023, a copy of which is available under the Company’s profile on SEDAR+ at www.sedarplus.ca.
While the counterparty claims that Optimi has failed to perform its obligations under the Supply Agreement, the Company disputes all such allegations and maintains the position that the termination is wrongful and that there was no breach of the Supply Agreement. The Company is evaluating available legal remedies and damages with respect to the counterparty’s actions.
For more information, please contact Michael Kydd at:
About Optimi
Optimi Health Corp. an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (“MDMA”), natural GMP-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.